In this video, Hardman & Co’s Head of Tax Advantaged Research, Dr Brian Moretta, discusses the EMV Evergreen EIS Fund and the findings from Hardman & Co’s latest review. Brian explains the fund’s investment strategy, its focus on early-stage deep tech and life science companies, and how EMV sources and selects investments. He also discusses EMV’s venture-build approach, post-investment support and the wider EMV Capital platform. The discussion also covers the fund’s track record to date, including its current portfolio and the broader EMV platform’s experience of realising investments. Topics covered: • Investment strategy and target returns • Deep tech and life science investments • Deal sourcing and the EMV Capital network • Venture building and post-investment support • The EIS portfolio and track record • EMV Capital’s wider investment experience Read Hardman & Co’s full review of the EMV Evergreen EIS Fund on our website. https://hardmanandco.com/research/tax-advantaged-research/emvc-evergreen-eis-fund/ Please note that this video is for information purposes only and does not constitute investment advice or a recommendation to invest. #eis #investment #venturecapital Important notice: This content has been prepared purely for information purposes, and should not be construed as an offer, or the solicitation of an offer, to buy or sell any security, product, service or investment. Nor should it be viewed as a substitute for viewers’ own due diligence. The companies or legal entities covered in this content may or may not pay us a fixed fee for this content to be made available. This content contains factually correct information at the time of publication which has been provided to us by our client to which the content relates, who have also confirmed that it has not been misleadingly presented. Investing in early-stage growth companies is speculative and involves a high degree of risk. An investor could lose all or a substantial amount of his or her investment, and the securities, legal entities or alternative investments mentioned in this content may not be suitable or appropriate for all investors. Access to liquidity may be totally or highly restricted. Each investor’s particular needs, investment objectives and financial situation were not taken into account in the preparation of this content. Each investor must make his or her own independent decisions and obtain their own independent advice regarding any information, projects, securities, tax treatment or financial instruments mentioned herein. The fact that Hardman & Co has made available through this content various information constitutes neither a recommendation to enter into a particular transaction nor a representation that any financial instrument is suitable or appropriate for you. Each investor should consider whether an investment strategy of the purchase or sale of any product or security is appropriate for them in the light of their investment needs, objectives and financial circumstances. For more information, please read our full disclaimers: www.hardmanandco.com/research-disclosures www.hardmanandco.com/disclaimer
